Details of the Drug Combinations

General Information of This Drug (ID: DM2TEOL)

Drug Name
Methotrexate   DM2TEOL
Synonyms
methotrexate; 1959/5/2; Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate
Indication
Disease Entry ICD 11 Status REF
Anterior urethra cancer N.A. Approved [1]
Burkitt lymphoma N.A. Approved [1]
Childhood acute lymphoblastic leukemia N.A. Approved [1]
Choriocarcinoma 2C75.0 Approved [2]
Gestational trophoblastic neoplasia 2F33-2F76 Approved [1]
Head and neck cancer 2D42 Approved [1]
Inflammation 1A00-CA43.1 Approved [1]
leukaemia 2A60-2B33 Approved [3]
Leukemia N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Mycosis fungoides 2B01 Approved [1]
Posterior urethra cancer N.A. Approved [1]
Psoriasis EA90 Approved [1]
Sensorineural hearing loss disorder N.A. Approved [1]
Urticaria EB00-EB05 Approved [1]
Proliferative vitreoretinopathy 9B78.2 Phase 3 [4]
Solid tumour/cancer 2A00-2F9Z Phase 3 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1/2 [5]
Rheumatoid arthritis FA20 Phase 1 [6]
Prostate cancer 2C82.0 Investigative [7]
⏷ Show the Full List of Indication(s)
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

500 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
10-hydroxycamptothecin + Methotrexate DC30Z5K 10-hydroxycamptothecin Invasive ductal carcinoma (Cell Line: T-47D) [8]
Acamprosate + Methotrexate DC7V00K Acamprosate Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Albendazole + Methotrexate DCJNMKU Albendazole Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Allopurinol + Methotrexate DC2WRIM Allopurinol Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Aminosalicylic acid + Methotrexate DC21AE0 Aminosalicylic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Amonafide + Methotrexate DCVWUQP Amonafide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [9]
Amonafide + Methotrexate DCIBR7Y Amonafide Glioma (Cell Line: SF-539) [9]
Amonafide + Methotrexate DCBUSS4 Amonafide Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Amonafide + Methotrexate DCWFD2X Amonafide Colon adenocarcinoma (Cell Line: COLO 205) [8]
Anastrozole + Methotrexate DCG1ZJB Anastrozole Adenocarcinoma (Cell Line: HCT116) [9]
Anastrozole + Methotrexate DC9Q7FO Anastrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Anastrozole + Methotrexate DCQ8LLF Anastrozole Anaplastic large cell lymphoma (Cell Line: SR) [9]
Anastrozole + Methotrexate DCHRPOO Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [9]
Anastrozole + Methotrexate DCI2IJG Anastrozole Lung adenocarcinoma (Cell Line: HOP-62) [9]
Anastrozole + Methotrexate DCJOBPG Anastrozole Colon adenocarcinoma (Cell Line: COLO 205) [8]
Arfolitixorin + Methotrexate DC4OCJ0 Arfolitixorin Invasive ductal carcinoma (Cell Line: T-47D) [8]
BIO-300 + Methotrexate DC60GM2 BIO-300 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [9]
BIO-300 + Methotrexate DCGNDCP BIO-300 Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
BIO-300 + Methotrexate DCUNFL1 BIO-300 Colon adenocarcinoma (Cell Line: COLO 205) [8]
BIO-300 + Methotrexate DCLN95I BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [10]
BIO-300 + Methotrexate DC7NHFT BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [10]
BIO-300 + Methotrexate DCKJFKI BIO-300 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [10]
Bleomycin + Methotrexate DCRX9C9 Bleomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [9]
Bleomycin + Methotrexate DC5IYQK Bleomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [9]
Bleomycin + Methotrexate DCJWQBN Bleomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Bleomycin + Methotrexate DCHKXIU Bleomycin Adenocarcinoma (Cell Line: HCT-15) [10]
Bleomycin + Methotrexate DCT48IM Bleomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [10]
Bortezomib + Methotrexate DCHMJWR Bortezomib Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Buspirone + Methotrexate DCBFSVS Buspirone Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
C646 + Methotrexate DC8RRS5 C646 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [9]
Cabazitaxel + Methotrexate DCKENNP Cabazitaxel Glioma (Cell Line: SF-539) [9]
Chlorzoxazone + Methotrexate DCMJJ5Q Chlorzoxazone Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Cinacalcet + Methotrexate DC5L5UW Cinacalcet Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Crizotinib + Methotrexate DCCQIDC Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [9]
Dacarbazine + Methotrexate DCB81PD Dacarbazine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [9]
Dacarbazine + Methotrexate DC2Q7AJ Dacarbazine Clear cell renal cell carcinoma (Cell Line: 786-0) [9]
Dacarbazine + Methotrexate DCPALH6 Dacarbazine Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Dactinomycin + Methotrexate DCQPB41 Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [10]
Dactinomycin + Methotrexate DCXIHTB Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [10]
Dexrazoxane + Methotrexate DCK74MY Dexrazoxane Clear cell renal cell carcinoma (Cell Line: A498) [9]
Dexrazoxane + Methotrexate DC64R63 Dexrazoxane Lung adenocarcinoma (Cell Line: MDA-MB-231) [10]
Dexrazoxane + Methotrexate DCWTX8V Dexrazoxane Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [10]
Dextromethorphan + Methotrexate DCFKQI0 Dextromethorphan Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Diazoxide + Methotrexate DCNKRM7 Diazoxide Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Diethylcarbamazine + Methotrexate DCYD5EZ Diethylcarbamazine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Diphenidol + Methotrexate DCV0TI8 Diphenidol Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Docetaxel + Methotrexate DCGCQ6D Docetaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Docetaxel + Methotrexate DC5174Y Docetaxel Anaplastic large cell lymphoma (Cell Line: SR) [9]
Docetaxel + Methotrexate DCCHYQF Docetaxel Astrocytoma (Cell Line: U251) [9]
Docetaxel + Methotrexate DCXWL3S Docetaxel Astrocytoma (Cell Line: SNB-19) [9]
Docetaxel + Methotrexate DCAIR3K Docetaxel Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Docetaxel + Methotrexate DCTK22R Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-5) [9]
Docetaxel + Methotrexate DCDN1DY Docetaxel Glioma (Cell Line: SF-539) [9]
Docetaxel + Methotrexate DCPKVHG Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [9]
Docetaxel + Methotrexate DCUUGVL Docetaxel Lung adenocarcinoma (Cell Line: NCI-H522) [9]
Docetaxel + Methotrexate DCTVTJ4 Docetaxel Prostate carcinoma (Cell Line: PC-3) [9]
Docetaxel + Methotrexate DCUYT17 Docetaxel Invasive ductal carcinoma (Cell Line: T-47D) [8]
Doxapram + Methotrexate DCTE010 Doxapram Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Doxorubicin + Methotrexate DCP4S8K Doxorubicin Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
DZNep + Methotrexate DCBFWSQ DZNep Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [9]
Efavirenz + Methotrexate DCZH4FN Efavirenz Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Epirubicin + Methotrexate DC8UW7M Epirubicin Invasive ductal carcinoma (Cell Line: T-47D) [8]
Epirubicin + Methotrexate DCGJT3I Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [10]
Ethambutol + Methotrexate DCAOU91 Ethambutol Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Ethinyl estradiol + Methotrexate DCG2CY5 Ethinyl estradiol Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Etonogestrel + Methotrexate DCI6FAE Etonogestrel Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Fluorouracil + Methotrexate DCC3NNC Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [8]
Fluorouracil + Methotrexate DCA10WS Fluorouracil Colon adenocarcinoma (Cell Line: LOVO) [8]
Fluorouracil + Methotrexate DCYEO3D Fluorouracil Invasive ductal carcinoma (Cell Line: T-47D) [8]
Fluorouracil + Methotrexate DCZXIUO Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [8]
Fluorouracil + Methotrexate DCU11IM Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [10]
Fluorouracil + Methotrexate DC76WFZ Fluorouracil Adenocarcinoma (Cell Line: OVCAR3) [10]
Fluorouracil + Methotrexate DCXOF6Z Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [10]
Fluorouracil + Methotrexate DCKQR25 Fluorouracil Adenocarcinoma (Cell Line: HT29) [10]
Fluorouracil + Methotrexate DCWHU6J Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [10]
FORMESTANE + Methotrexate DCWC3NF FORMESTANE Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
FORMESTANE + Methotrexate DCW84T6 FORMESTANE Lung adenocarcinoma (Cell Line: EKVX) [9]
Fulvestrant + Methotrexate DCLURX1 Fulvestrant Melanoma (Cell Line: MALME-3M) [9]
Fulvestrant + Methotrexate DC2ITL1 Fulvestrant Invasive ductal carcinoma (Cell Line: T-47D) [8]
Gefitinib + Methotrexate DCX2VUW Gefitinib Adenocarcinoma (Cell Line: HCC-2998) [9]
Gefitinib + Methotrexate DCK8YK5 Gefitinib Chronic myelogenous leukemia (Cell Line: K-562) [9]
Gefitinib + Methotrexate DCFKUIP Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [9]
Gefitinib + Methotrexate DCYSTMC Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [9]
Gefitinib + Methotrexate DC00TDD Gefitinib Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Gefitinib + Methotrexate DCJ6ZRH Gefitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Gefitinib + Methotrexate DCQRZBI Gefitinib Prostate carcinoma (Cell Line: PC-3) [9]
Gefitinib + Methotrexate DCJT2HC Gefitinib Carcinoma (Cell Line: MCF7) [8]
Gefitinib + Methotrexate DC5K6ZU Gefitinib Invasive ductal carcinoma (Cell Line: HS 578T) [8]
GINKGOLIDE A + Methotrexate DC1GR7Y GINKGOLIDE A Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
GYKI-52466 + Methotrexate DCSOB61 GYKI-52466 Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Indazole derivative 5 + Methotrexate DC7G92S Indazole derivative 5 Astrocytoma (Cell Line: U251) [9]
Indazole derivative 5 + Methotrexate DCADNYR Indazole derivative 5 Invasive ductal carcinoma (Cell Line: T-47D) [8]
Isoproterenol + Methotrexate DCSZJIN Isoproterenol Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
JNK-IN-8 + Methotrexate DCH108N JNK-IN-8 Anaplastic large cell lymphoma (Cell Line: SR) [9]
JNK-IN-8 + Methotrexate DCBMDY4 JNK-IN-8 Lung adenocarcinoma (Cell Line: MDA-MB-231) [10]
L-165041 + Methotrexate DC26PGU L-165041 Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Lapatinib + Methotrexate DCYK6YC Lapatinib Anaplastic large cell lymphoma (Cell Line: SR) [10]
Lefaxin + Methotrexate DC2SM7Z Lefaxin Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Lenalidomide + Methotrexate DCHUQJD Lenalidomide Chronic myelogenous leukemia (Cell Line: K-562) [9]
Lenalidomide + Methotrexate DC5IXDC Lenalidomide Clear cell renal cell carcinoma (Cell Line: 786-0) [9]
Lenalidomide + Methotrexate DCZ64PP Lenalidomide Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [9]
Lenalidomide + Methotrexate DCW630K Lenalidomide Renal cell carcinoma (Cell Line: UO-31) [9]
Lenalidomide + Methotrexate DC2RRS2 Lenalidomide Adenocarcinoma (Cell Line: A549) [10]
Lenalidomide + Methotrexate DCIEWHP Lenalidomide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [10]
Lenalidomide + Methotrexate DCNK0XN Lenalidomide Lung adenocarcinoma (Cell Line: MDA-MB-231) [10]
Lenalidomide + Methotrexate DCDXUXT Lenalidomide Prostate carcinoma (Cell Line: PC-3) [10]
Letrozole + Methotrexate DCG64OD Letrozole Adenocarcinoma (Cell Line: HCT-15) [9]
Letrozole + Methotrexate DC540QX Letrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Letrozole + Methotrexate DCN3LF8 Letrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [9]
Letrozole + Methotrexate DCLXS2C Letrozole Amelanotic melanoma (Cell Line: M14) [9]
Letrozole + Methotrexate DCBAUZU Letrozole Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [9]
Letrozole + Methotrexate DCIE6AG Letrozole Clear cell renal cell carcinoma (Cell Line: 786-0) [9]
Letrozole + Methotrexate DC25JQI Letrozole Glioma (Cell Line: SF-539) [9]
Letrozole + Methotrexate DC545NE Letrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [9]
Letrozole + Methotrexate DC0YDVK Letrozole Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Letrozole + Methotrexate DC4SZCJ Letrozole Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Letrozole + Methotrexate DCBCY2Q Letrozole Malignant melanoma (Cell Line: UACC62) [9]
Letrozole + Methotrexate DCL4918 Letrozole Melanoma (Cell Line: UACC-257) [9]
Letrozole + Methotrexate DC7YPZF Letrozole Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Letrozole + Methotrexate DCXMYNH Letrozole Invasive ductal carcinoma (Cell Line: BT-549) [8]
Levamisole + Methotrexate DCWVXS8 Levamisole Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Linagliptin + Methotrexate DCL2DMT Linagliptin Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
LY2157299 + Methotrexate DCLOBLC LY2157299 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [9]
LY3023414 + Methotrexate DCVNIFZ LY3023414 Hepatoblastoma (Cell Line: HB3) [10]
Maraviroc + Methotrexate DCKGHQ0 Maraviroc Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Mechlorethamine + Methotrexate DC4DP9D Mechlorethamine Invasive ductal carcinoma (Cell Line: T-47D) [8]
Mechlorethamine + Methotrexate DCW7RQY Mechlorethamine Lung adenocarcinoma (Cell Line: MDA-MB-231) [10]
Meclofenamic acid + Methotrexate DC2DFZU Meclofenamic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Mesalazine + Methotrexate DCRJKQ3 Mesalazine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Ribavirin-TP DCTK72A Ribavirin-TP Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Sertraline DCGV1TC Sertraline Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Pentostatin DCU48OJ Pentostatin Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + GSK461364 DCHHJMJ GSK461364 Ewing sarcoma (Cell Line: TC-71) [9]
Methotrexate + Baclofen DCWY2O7 Baclofen Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Gefitinib DCSA7GH Gefitinib Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Clindamycin DCJC8XV Clindamycin Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + PD-0325901 DCNIQOH PD-0325901 Adenocarcinoma (Cell Line: OVCAR3) [9]
Methotrexate + PD-0325901 DCO0NF3 PD-0325901 Adenocarcinoma (Cell Line: NCIH1650) [9]
Methotrexate + PD-0325901 DCMJV0L PD-0325901 Adenocarcinoma (Cell Line: NCIH23) [9]
Methotrexate + PD-0325901 DC6SBDF PD-0325901 Germ cell tumour (Cell Line: PA1) [9]
Methotrexate + PD-0325901 DCFGZ9L PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Methotrexate + PD-0325901 DCQY2DZ PD-0325901 Malignant melanoma (Cell Line: HT144) [9]
Methotrexate + PD-0325901 DC293HJ PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [9]
Methotrexate + PD-0325901 DC4E89G PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [9]
Methotrexate + PD-0325901 DC5112T PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [9]
Methotrexate + PD-0325901 DCB63BB PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Methotrexate + Lumefantrine DC62WWB Lumefantrine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Hepzato DCDV2MP Hepzato Adenocarcinoma (Cell Line: HCT-15) [9]
Methotrexate + Hepzato DC2IR9R Hepzato Melanoma (Cell Line: MALME-3M) [9]
Methotrexate + Citalopram DCXMC2C Citalopram Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Ixabepilone DCL8TCC Ixabepilone Glioma (Cell Line: SF-539) [9]
Methotrexate + Crotamiton DC8ZZC4 Crotamiton Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Dactinomycin DCS9ZWJ Dactinomycin Adenocarcinoma (Cell Line: HCC-2998) [9]
Methotrexate + Dactinomycin DC7EC49 Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Methotrexate + Dactinomycin DCX04EK Dactinomycin Renal cell carcinoma (Cell Line: SN12C) [9]
Methotrexate + Lapatinib DCWHNE1 Lapatinib Adenocarcinoma (Cell Line: NCIH23) [9]
Methotrexate + Lapatinib DCQT0RH Lapatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [9]
Methotrexate + Lapatinib DCEHH9Q Lapatinib Malignant melanoma (Cell Line: UACC62) [9]
Methotrexate + Lapatinib DCODCV6 Lapatinib Prostate carcinoma (Cell Line: LNCAP) [9]
Methotrexate + Epinephrine DCGBT6I Epinephrine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Furazolidone DCSA3AB Furazolidone Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Chlorphenesin DCZ3885 Chlorphenesin Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + MK-1775 DCHHKH2 MK-1775 Adenocarcinoma (Cell Line: OVCAR3) [9]
Methotrexate + MK-1775 DCYGM6J MK-1775 Adenocarcinoma (Cell Line: NCIH23) [9]
Methotrexate + MK-1775 DCNY1KW MK-1775 Adenocarcinoma (Cell Line: HT29) [9]
Methotrexate + MK-1775 DCMGF04 MK-1775 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Methotrexate + PMID28460551-Compound-2 DC1A101 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [9]
Methotrexate + PMID28460551-Compound-2 DCLCKJ2 PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [9]
Methotrexate + PMID28460551-Compound-2 DCSD5GL PMID28460551-Compound-2 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Methotrexate + LIAROZOLE DCPEZDF LIAROZOLE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Methotrexate + Dihydroergotamine DCWSUTZ Dihydroergotamine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Isoniazid DCDMMTC Isoniazid Adenocarcinoma (Cell Line: HCT116) [9]
Methotrexate + Isoniazid DC6DYTX Isoniazid Melanoma (Cell Line: MALME-3M) [9]
Methotrexate + Vinblastine DC3VBDK Vinblastine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Arsenic trioxide DCV0GGD Arsenic trioxide Melanoma (Cell Line: SK-MEL-2) [9]
Methotrexate + RTB101 DCM1FC4 RTB101 Adenocarcinoma (Cell Line: NCIH520) [9]
Methotrexate + RTB101 DCU92EV RTB101 Malignant melanoma (Cell Line: HT144) [9]
Methotrexate + RTB101 DCPF8VI RTB101 Malignant melanoma (Cell Line: SKMEL30) [9]
Methotrexate + RTB101 DC1IHTV RTB101 Mesothelioma (Cell Line: MSTO) [9]
Methotrexate + SCH-900776 DCB4GY2 SCH-900776 Adenocarcinoma (Cell Line: OVCAR3) [9]
Methotrexate + SCH-900776 DCRVF6R SCH-900776 Adenocarcinoma (Cell Line: NCIH23) [9]
Methotrexate + SCH-900776 DCGCF91 SCH-900776 Ewing sarcoma (Cell Line: TC-71) [9]
Methotrexate + SCH-900776 DCPCMK3 SCH-900776 Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Methotrexate + SCH-900776 DCV3M2S SCH-900776 Malignant melanoma (Cell Line: A375) [9]
Methotrexate + SCH-900776 DCMYLCC SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [9]
Methotrexate + SCH-900776 DCKWCI8 SCH-900776 Mesothelioma (Cell Line: MSTO) [9]
Methotrexate + SCH-900776 DCK3GO4 SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [9]
Methotrexate + SCH-900776 DCKA44C SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Methotrexate + Sivelestat DC5ABBC Sivelestat Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Ezetimibe DCBKP6M Ezetimibe Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Eltanexor oral DCQG38B Eltanexor oral Ewing sarcoma (Cell Line: TC-71) [9]
Methotrexate + Eltanexor oral DCE9PQP Eltanexor oral Hodgkin lymphoma (Cell Line: U-HO1) [9]
Methotrexate + Nilotinib DC9EXNL Nilotinib Astrocytoma (Cell Line: U251) [9]
Methotrexate + Nilotinib DCSQ13N Nilotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [9]
Methotrexate + Dexmedetomidine DCLF9IQ Dexmedetomidine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Tranexamic acid DCYI1GN Tranexamic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Pepstatin DCG65PG Pepstatin Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Steroid derivative 1 DC3Y75U Steroid derivative 1 Ewing sarcoma (Cell Line: TC-71) [9]
Methotrexate + SNX-2112 DCMAX42 SNX-2112 Adenocarcinoma (Cell Line: OVCAR3) [9]
Methotrexate + SNX-2112 DCK7MV6 SNX-2112 Germ cell tumour (Cell Line: PA1) [9]
Methotrexate + SNX-2112 DCYNUOX SNX-2112 Malignant melanoma (Cell Line: A375) [9]
Methotrexate + SNX-2112 DCWBDCD SNX-2112 Malignant melanoma (Cell Line: HT144) [9]
Methotrexate + SNX-2112 DCJOUYL SNX-2112 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Methotrexate + Isosorbide dinitrate DCMOIPZ Isosorbide dinitrate Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + SCH 727965 DCJ4YRG SCH 727965 Adenocarcinoma (Cell Line: OVCAR3) [9]
Methotrexate + SCH 727965 DCN6B2L SCH 727965 Germ cell tumour (Cell Line: PA1) [9]
Methotrexate + SCH 727965 DC2ZPNQ SCH 727965 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Methotrexate + Erlotinib DC2N846 Erlotinib Adenocarcinoma (Cell Line: A427) [9]
Methotrexate + Erlotinib DC82KVI Erlotinib Adenocarcinoma (Cell Line: NCIH1650) [9]
Methotrexate + Erlotinib DCBFOQA Erlotinib Adenocarcinoma (Cell Line: NCIH23) [9]
Methotrexate + Erlotinib DCBJJZ2 Erlotinib Adenocarcinoma (Cell Line: SW-620) [9]
Methotrexate + Erlotinib DCDWV4E Erlotinib Germ cell tumour (Cell Line: PA1) [9]
Methotrexate + Erlotinib DCMIU92 Erlotinib Malignant melanoma (Cell Line: A375) [9]
Methotrexate + Erlotinib DCIG80N Erlotinib Malignant melanoma (Cell Line: UACC62) [9]
Methotrexate + Erlotinib DCO3XY6 Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Methotrexate + Erlotinib DCPQUG8 Erlotinib Prostate carcinoma (Cell Line: LNCAP) [9]
Methotrexate + Erlotinib DCP0HK8 Erlotinib Prostate carcinoma (Cell Line: VCAP) [9]
Methotrexate + Ifosfamide DCHCKYT Ifosfamide Chronic myelogenous leukemia (Cell Line: K-562) [9]
Methotrexate + Memantine DCG75B3 Memantine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Metformin DCHIAWM Metformin Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Raloxifene DCLIDDT Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Methotrexate + Raloxifene DC20EJM Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [9]
Methotrexate + Raloxifene DCR6KUC Raloxifene Lung adenocarcinoma (Cell Line: HOP-62) [9]
Methotrexate + Raloxifene DCAZI1W Raloxifene Melanoma (Cell Line: MALME-3M) [9]
Methotrexate + Phenprocoumon DCYW9SW Phenprocoumon Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Cilastatin DCXFTM6 Cilastatin Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + JZL195 DCI3OON JZL195 Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Ginsenoside Rb1 DCGPFVC Ginsenoside Rb1 Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Phensuximide DCCVTBB Phensuximide Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + MK-5108 DCE4CEO MK-5108 Adenocarcinoma (Cell Line: NCIH23) [9]
Methotrexate + MK-5108 DCO8U4X MK-5108 Adenocarcinoma (Cell Line: COLO320DM) [9]
Methotrexate + MK-5108 DCD0OMB MK-5108 Malignant melanoma (Cell Line: RPMI7951) [9]
Methotrexate + MK-5108 DCPRYQC MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [9]
Methotrexate + MK-5108 DCIP3AB MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Methotrexate + Bendamustine hydrochloride DCWYH01 Bendamustine hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Methotrexate + Fluspirilene DCLWG40 Fluspirilene Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Ciprofibrate DCH04VF Ciprofibrate Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Sitagliptin DCGRQDU Sitagliptin Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Mecamylamine DCJLEOI Mecamylamine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Sirolimus DCJ5VCR Sirolimus Adenocarcinoma (Cell Line: HCT116) [9]
Methotrexate + Sirolimus DCOYJV1 Sirolimus Lung adenocarcinoma (Cell Line: NCI-H522) [9]
Methotrexate + Mitomycin DCUTT93 Mitomycin Anaplastic large cell lymphoma (Cell Line: SR) [9]
Methotrexate + Mitomycin DCNQZN6 Mitomycin Glioma (Cell Line: SF-295) [9]
Methotrexate + Mitomycin DCKW79H Mitomycin Melanoma (Cell Line: MALME-3M) [9]
Methotrexate + Dichlorphenamide DCG7VP3 Dichlorphenamide Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + SY-1425 DC9DXF4 SY-1425 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [9]
Methotrexate + SY-1425 DC5TNHP SY-1425 Lung adenocarcinoma (Cell Line: HOP-62) [9]
Methotrexate + Clopidogrel DCAEP3X Clopidogrel Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Sulfapyridine DCCOR4D Sulfapyridine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Eflornithine DCXJ6F2 Eflornithine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + PF-02545920 DC1LIIC PF-02545920 Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Altretamine DCP58AR Altretamine Melanoma (Cell Line: MALME-3M) [9]
Methotrexate + Tiagabine DCME2J3 Tiagabine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Oseltamivir DCIALHR Oseltamivir Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Fenoprofen DC8WLAU Fenoprofen Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Ridaforolimus DCS67P8 Ridaforolimus Adenocarcinoma (Cell Line: CAOV3) [9]
Methotrexate + Ridaforolimus DCWYVAB Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [9]
Methotrexate + Ridaforolimus DCZPHQM Ridaforolimus Adenocarcinoma (Cell Line: NCIH23) [9]
Methotrexate + Ridaforolimus DCGLFI4 Ridaforolimus Adenocarcinoma (Cell Line: DLD1) [9]
Methotrexate + Ridaforolimus DC8EQVW Ridaforolimus Adenocarcinoma (Cell Line: SW-620) [9]
Methotrexate + Ridaforolimus DCOUCLT Ridaforolimus Amelanotic melanoma (Cell Line: A2058) [9]
Methotrexate + Ridaforolimus DC6LZ9N Ridaforolimus Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Methotrexate + Ridaforolimus DCN9KW5 Ridaforolimus Malignant melanoma (Cell Line: A375) [9]
Methotrexate + Ridaforolimus DCORPAT Ridaforolimus Mesothelioma (Cell Line: MSTO) [9]
Methotrexate + MK-4827 DCB2VED MK-4827 Adenocarcinoma (Cell Line: A427) [9]
Methotrexate + MK-4827 DCLG5GR MK-4827 Adenocarcinoma (Cell Line: NCIH23) [9]
Methotrexate + MK-4827 DCECWHE MK-4827 Germ cell tumour (Cell Line: PA1) [9]
Methotrexate + MK-4827 DCGPNZR MK-4827 Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Methotrexate + MK-4827 DC3PP3V MK-4827 Malignant melanoma (Cell Line: HT144) [9]
Methotrexate + MK-4827 DCXIG3C MK-4827 Malignant melanoma (Cell Line: SKMEL30) [9]
Methotrexate + MK-4827 DCDUK5H MK-4827 Mesothelioma (Cell Line: MSTO) [9]
Methotrexate + Pargyline DCDXDOQ Pargyline Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Idarubicin DC32ZUJ Idarubicin Adenocarcinoma (Cell Line: NCIH23) [9]
Methotrexate + Idarubicin DCMLDLK Idarubicin Adenocarcinoma (Cell Line: NCIH520) [9]
Methotrexate + Idarubicin DC61CFB Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [9]
Methotrexate + BRL-15572 DCH1QZG BRL-15572 Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Imatinib DCCEQWP Imatinib Adenocarcinoma (Cell Line: OVCAR3) [9]
Methotrexate + Imatinib DCRHP4W Imatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Methotrexate + Imatinib DCKH32D Imatinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [9]
Methotrexate + Imatinib DC5KNQD Imatinib Glioma (Cell Line: SF-539) [9]
Methotrexate + Imatinib DCQ5I5A Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [9]
Methotrexate + Imatinib DC0VZ3S Imatinib Malignant melanoma (Cell Line: LOX IMVI) [9]
Methotrexate + Imatinib DC6YDJR Imatinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Methotrexate + Imatinib DCCJSX1 Imatinib Renal cell carcinoma (Cell Line: SN12C) [9]
Methotrexate + Atenolol DC6ZEZS Atenolol Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Pramipexole DCPFKN0 Pramipexole Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Bortezomib DC8WDIW Bortezomib Malignant melanoma (Cell Line: A375) [9]
Methotrexate + Methylene blue DC20ZB7 Methylene blue Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Moricizine DC4FMV0 Moricizine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + GSK525762 DCP6UNG GSK525762 Adenocarcinoma (Cell Line: NCIH520) [9]
Methotrexate + GSK525762 DCSD8C3 GSK525762 Malignant melanoma (Cell Line: SKMEL30) [9]
Methotrexate + GSK525762 DCC4E4U GSK525762 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Methotrexate + Enalaprilat DCY306C Enalaprilat Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Teriflunomide DCXRCZM Teriflunomide Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Novobiocin DCE3N9R Novobiocin Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Chlorambucil DCUC9DF Chlorambucil Adenocarcinoma (Cell Line: DU-145) [9]
Methotrexate + Chlorambucil DCIZ233 Chlorambucil High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [9]
Methotrexate + Brincidofovir DCVHOON Brincidofovir Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Sorafenib DCE161Q Sorafenib Adenocarcinoma (Cell Line: NCIH23) [9]
Methotrexate + Sorafenib DCCHAT4 Sorafenib Adenocarcinoma (Cell Line: DLD1) [9]
Methotrexate + Sorafenib DCT07KR Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Methotrexate + Desoxycorticosterone pivalate DCX9M37 Desoxycorticosterone pivalate Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + ER819762 DCPUIIV ER819762 Astrocytoma (Cell Line: SNB-19) [9]
Methotrexate + ER819762 DC91J6T ER819762 Chronic myelogenous leukemia (Cell Line: K-562) [9]
Methotrexate + Chloroquine DC7K4X4 Chloroquine DD2 (Cell Line: DD2) [9]
Methotrexate + MK-2206 DCIH26S MK-2206 Adenocarcinoma (Cell Line: A427) [9]
Methotrexate + MK-2206 DCH2SOV MK-2206 Adenocarcinoma (Cell Line: NCIH23) [9]
Methotrexate + MK-2206 DCAVZFM MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [9]
Methotrexate + MK-2206 DC4MJ31 MK-2206 Amelanotic melanoma (Cell Line: A2058) [9]
Methotrexate + MK-2206 DCELOTU MK-2206 Germ cell tumour (Cell Line: PA1) [9]
Methotrexate + MK-2206 DCPHSA2 MK-2206 Malignant melanoma (Cell Line: HT144) [9]
Methotrexate + MK-2206 DCQBJVK MK-2206 Malignant melanoma (Cell Line: SKMEL30) [9]
Methotrexate + MK-2206 DCVOFG2 MK-2206 Malignant melanoma (Cell Line: UACC62) [9]
Methotrexate + MK-2206 DC2D537 MK-2206 Mesothelioma (Cell Line: MSTO) [9]
Methotrexate + MK-2206 DCUQDE9 MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [9]
Methotrexate + MK-2206 DCB6HWV MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Methotrexate + Romidepsin DCLYAPT Romidepsin Ewing sarcoma (Cell Line: TC-71) [9]
Methotrexate + Piperaquine DC8KR49 Piperaquine DD2 (Cell Line: DD2) [9]
Methotrexate + Piperaquine DC8EDXT Piperaquine Hepatoblastoma (Cell Line: HB3) [9]
Methotrexate + Pomalidomide DC1B9WO Pomalidomide Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Pomalidomide DC6TA2Z Pomalidomide Melanoma (Cell Line: MALME-3M) [9]
Methotrexate + Mercaptopurine DCUBR59 Mercaptopurine Adenocarcinoma (Cell Line: DU-145) [9]
Methotrexate + Mycophenolic acid DCU15GE Mycophenolic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Mepacrine DCS13Z0 Mepacrine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Methotrexate + Mepacrine DCBV5GL Mepacrine Amelanotic melanoma (Cell Line: M14) [9]
Methotrexate + Mepacrine DCV7XXJ Mepacrine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [9]
Methotrexate + Mepacrine DC2E97P Mepacrine Chronic myelogenous leukemia (Cell Line: K-562) [9]
Methotrexate + Pyronaridine DCVBDIJ Pyronaridine DD2 (Cell Line: DD2) [9]
Methotrexate + Lacosamide DCXEWHA Lacosamide Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Iloprost DCJG7PU Iloprost Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Fludarabine DCAVF4P Fludarabine Lung adenocarcinoma (Cell Line: EKVX) [9]
Methotrexate + Nabilone DCYSGAO Nabilone Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Sumatriptan DC0FXBF Sumatriptan Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Aminolevulinic Acid Hydrochloride DC3J00Z Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: DU-145) [9]
Methotrexate + Aminolevulinic Acid Hydrochloride DCG2ODZ Aminolevulinic Acid Hydrochloride Astrocytoma (Cell Line: U251) [9]
Methotrexate + Cevimeline DC28KA0 Cevimeline Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Cerivastatin DCLTULE Cerivastatin Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Busulfan DCJZ0MU Busulfan Anaplastic large cell lymphoma (Cell Line: SR) [9]
Methotrexate + Hydroxychloroquine DCLQ05L Hydroxychloroquine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Atovaquone DC84L5U Atovaquone Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Atovaquone DC5Z6Z3 Atovaquone DD2 (Cell Line: DD2) [9]
Methotrexate + Atovaquone DCYQK2L Atovaquone Hepatoblastoma (Cell Line: HB3) [9]
Methotrexate + CB3304 DCWKRYW CB3304 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [9]
Methotrexate + ML323 DCC95JA ML323 Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Raltegravir DCDU2T1 Raltegravir Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Ibrutinib DCAU7HL Ibrutinib Diffuse large B cell lymphoma (Cell Line: TMD8) [9]
Methotrexate + AS-1949490 DCOSQT0 AS-1949490 Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Methotrexate + Dasatinib DC4L6AG Dasatinib Adenocarcinoma (Cell Line: NCIH23) [9]
Methotrexate + Dasatinib DCXU18P Dasatinib Germ cell tumour (Cell Line: PA1) [9]
Methotrexate + Dasatinib DCKNNR0 Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [9]
Methotrexate + Dasatinib DC0NDDZ Dasatinib Prostate carcinoma (Cell Line: VCAP) [9]
Methotrexate + Pentostatin DC0X6DO Pentostatin Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Methotrexate + PD-0325901 DC2ZK87 PD-0325901 Breast carcinoma (Cell Line: KPL1) [8]
Methotrexate + PD-0325901 DCWPOB5 PD-0325901 Carcinoma (Cell Line: EFM192B) [8]
Methotrexate + PD-0325901 DCXJNA2 PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [8]
Methotrexate + Lapatinib DCWLR3W Lapatinib Colon adenocarcinoma (Cell Line: LOVO) [8]
Methotrexate + MK-1775 DCA6J41 MK-1775 Invasive ductal carcinoma (Cell Line: T-47D) [8]
Methotrexate + PMID28460551-Compound-2 DCBFJ7U PMID28460551-Compound-2 Breast carcinoma (Cell Line: ZR751) [8]
Methotrexate + PMID28460551-Compound-2 DCDC13Q PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [8]
Methotrexate + PMID28460551-Compound-2 DCZLHLS PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [8]
Methotrexate + PMID28460551-Compound-2 DC2MVM6 PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [8]
Methotrexate + RTB101 DCLJKGK RTB101 Carcinoma (Cell Line: OV90) [8]
Methotrexate + RTB101 DCNKCUV RTB101 Carcinoma (Cell Line: EFM192B) [8]
Methotrexate + RTB101 DCEQQJY RTB101 Rectal adenocarcinoma (Cell Line: SW837) [8]
Methotrexate + SCH-900776 DC5X33B SCH-900776 Carcinoma (Cell Line: EFM192B) [8]
Methotrexate + SNX-2112 DCI2IJ3 SNX-2112 Carcinoma (Cell Line: OV90) [8]
Methotrexate + SNX-2112 DC1QK32 SNX-2112 Carcinoma (Cell Line: EFM192B) [8]
Methotrexate + SNX-2112 DCIVNUX SNX-2112 Colon adenocarcinoma (Cell Line: LOVO) [8]
Methotrexate + SNX-2112 DC7LFYZ SNX-2112 Rectal adenocarcinoma (Cell Line: SW837) [8]
Methotrexate + SCH 727965 DCZEAQA SCH 727965 Carcinoma (Cell Line: EFM192B) [8]
Methotrexate + SCH 727965 DC9GQ7B SCH 727965 Colon adenocarcinoma (Cell Line: LOVO) [8]
Methotrexate + Erlotinib DC0WXBB Erlotinib Carcinoma (Cell Line: EFM192B) [8]
Methotrexate + Raloxifene DCMMTUY Raloxifene Invasive ductal carcinoma (Cell Line: T-47D) [8]
Methotrexate + Mitomycin DCWYJIF Mitomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Methotrexate + Mitomycin DCAFQBG Mitomycin Invasive ductal carcinoma (Cell Line: BT-549) [8]
Methotrexate + Altretamine DCM9TBI Altretamine Invasive ductal carcinoma (Cell Line: T-47D) [8]
Methotrexate + Ridaforolimus DCLBVE5 Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [8]
Methotrexate + Ridaforolimus DCX9LJX Ridaforolimus Colon carcinoma (Cell Line: RKO) [8]
Methotrexate + Ridaforolimus DCPILFH Ridaforolimus Rectal adenocarcinoma (Cell Line: SW837) [8]
Methotrexate + MK-4827 DCTM1LT MK-4827 Carcinoma (Cell Line: EFM192B) [8]
Methotrexate + MK-4827 DCVUBB0 MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [8]
Methotrexate + Idarubicin DC38RMV Idarubicin Colon adenocarcinoma (Cell Line: LOVO) [8]
Methotrexate + Imatinib DC8EJI1 Imatinib Carcinoma (Cell Line: MCF7) [8]
Methotrexate + Imatinib DCMZNJ7 Imatinib Colon carcinoma (Cell Line: KM12) [8]
Methotrexate + Bortezomib DCYQ089 Bortezomib Rectal adenocarcinoma (Cell Line: SW837) [8]
Methotrexate + GSK525762 DCVXMPX GSK525762 Rectal adenocarcinoma (Cell Line: SW837) [8]
Methotrexate + Sorafenib DC39P7E Sorafenib Carcinoma (Cell Line: EFM192B) [8]
Methotrexate + Sorafenib DCGGCKA Sorafenib Rectal adenocarcinoma (Cell Line: SW837) [8]
Methotrexate + ER819762 DCSRRDC ER819762 Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Methotrexate + MK-2206 DCRKZ1C MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [8]
Methotrexate + MK-2206 DCDIEF2 MK-2206 Carcinoma (Cell Line: EFM192B) [8]
Methotrexate + MK-2206 DCL7TNI MK-2206 Invasive ductal carcinoma (Cell Line: T-47D) [8]
Methotrexate + MK-2206 DC88BRL MK-2206 Rectal adenocarcinoma (Cell Line: SW837) [8]
Naltrexone + Methotrexate DC3XFDU Naltrexone Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Olmesartan medoxomil + Methotrexate DCWBID6 Olmesartan medoxomil Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
PFI-3 + Methotrexate DC989FY PFI-3 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [9]
PFK-158 + Methotrexate DCYUAR2 PFK-158 Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Picoplatin + Methotrexate DCRR2TN Picoplatin Lung adenocarcinoma (Cell Line: MDA-MB-231) [10]
Picoplatin + Methotrexate DC1U53U Picoplatin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [10]
Picoplatin + Methotrexate DCGKUYA Picoplatin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [10]
Plicamycin + Methotrexate DC0QRDW Plicamycin Anaplastic large cell lymphoma (Cell Line: SR) [9]
Plicamycin + Methotrexate DC723RF Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [10]
Plicamycin + Methotrexate DCMDXO2 Plicamycin Large cell lung carcinoma (Cell Line: NCI-H460) [10]
Plicamycin + Methotrexate DC7LI96 Plicamycin Malignant melanoma (Cell Line: UACC62) [10]
PMID28460551-Compound-2 + Methotrexate DCOAWB5 PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [8]
PMID28870136-Compound-43 + Methotrexate DCQQNGD PMID28870136-Compound-43 Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Pralatrexate + Methotrexate DC65E5O Pralatrexate Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Pralatrexate + Methotrexate DCFS4T7 Pralatrexate Astrocytoma (Cell Line: SNB-19) [9]
Pralatrexate + Methotrexate DCB5C0A Pralatrexate Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [9]
Pralatrexate + Methotrexate DC7B2QD Pralatrexate Clear cell renal cell carcinoma (Cell Line: A498) [9]
Pralatrexate + Methotrexate DCB7YFH Pralatrexate Clear cell renal cell carcinoma (Cell Line: CAKI-1) [9]
Pralatrexate + Methotrexate DC5NUXL Pralatrexate Glioma (Cell Line: SF-268) [9]
Pralatrexate + Methotrexate DC41Z51 Pralatrexate Renal cell carcinoma (Cell Line: SN12C) [9]
Pralatrexate + Methotrexate DCG5UU4 Pralatrexate Renal cell carcinoma (Cell Line: UO-31) [9]
Pralatrexate + Methotrexate DCADBK1 Pralatrexate Carcinoma (Cell Line: MCF7) [8]
Pralatrexate + Methotrexate DCEN5CG Pralatrexate Colon carcinoma (Cell Line: KM12) [8]
Pralatrexate + Methotrexate DCGJH0Q Pralatrexate Invasive ductal carcinoma (Cell Line: BT-549) [8]
Pralatrexate + Methotrexate DCWUV3W Pralatrexate Adenocarcinoma (Cell Line: DU-145) [10]
Pralatrexate + Methotrexate DCR4JAO Pralatrexate Adenocarcinoma (Cell Line: A549) [10]
Pralatrexate + Methotrexate DC4HNDA Pralatrexate Adenocarcinoma (Cell Line: HT29) [10]
Pralatrexate + Methotrexate DCYZ8CW Pralatrexate Adenocarcinoma (Cell Line: HCT-15) [10]
Pralatrexate + Methotrexate DCLDYQF Pralatrexate Amelanotic melanoma (Cell Line: MDA-MB-435) [10]
Pralatrexate + Methotrexate DC0FYMM Pralatrexate Large cell lung carcinoma (Cell Line: NCI-H460) [10]
Pralatrexate + Methotrexate DC2O41S Pralatrexate Lung adenocarcinoma (Cell Line: HOP-62) [10]
Pralatrexate + Methotrexate DCZSJBS Pralatrexate Malignant melanoma (Cell Line: UACC62) [10]
Pralatrexate + Methotrexate DC4TQ3O Pralatrexate Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [10]
Pralatrexate + Methotrexate DCFM3T7 Pralatrexate Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [10]
Pramipexole + Methotrexate DCEGQN0 Pramipexole Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Probenecid + Methotrexate DC7D973 Probenecid Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Pyrazinamide + Methotrexate DC0JX6R Pyrazinamide Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Raloxifene + Methotrexate DCUOI4U Raloxifene Adenocarcinoma (Cell Line: A549) [10]
Ramelteon + Methotrexate DCZ34P8 Ramelteon Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Romidepsin + Methotrexate DCTARHH Romidepsin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Romidepsin + Methotrexate DCZBNDV Romidepsin Anaplastic large cell lymphoma (Cell Line: SR) [9]
SB-505124 + Methotrexate DCYPLFP SB-505124 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [9]
Silver sulfadiazine + Methotrexate DC3BNJQ Silver sulfadiazine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Sirolimus + Methotrexate DCM9CYL Sirolimus Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [9]
Sirolimus + Methotrexate DCR7109 Sirolimus Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [9]
Sirolimus + Methotrexate DCLB87L Sirolimus Invasive ductal carcinoma (Cell Line: T-47D) [8]
Sirolimus + Methotrexate DCK25CW Sirolimus Adenocarcinoma (Cell Line: HCT-15) [10]
Sirolimus + Methotrexate DCNIBDF Sirolimus Cutaneous melanoma (Cell Line: SK-MEL-5) [10]
Sirolimus + Methotrexate DCRH0M1 Sirolimus Malignant melanoma (Cell Line: UACC62) [10]
Sirolimus + Methotrexate DCKKDR1 Sirolimus Prostate carcinoma (Cell Line: PC-3) [10]
Sorafenib + Methotrexate DCP9A5I Sorafenib Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Sorafenib + Methotrexate DCYUIFX Sorafenib Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Spironolactone + Methotrexate DC2ZCCB Spironolactone Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Sulfinpyrazone + Methotrexate DC29EQU Sulfinpyrazone Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Tacrine + Methotrexate DCJ97BC Tacrine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Tamoxifen + Methotrexate DCO2JRJ Tamoxifen Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
TEM + Methotrexate DC26Q2U TEM Astrocytoma (Cell Line: SNB-19) [9]
TEM + Methotrexate DCE11Z3 TEM Glioma (Cell Line: SF-295) [9]
TEM + Methotrexate DC5E2JZ TEM Adenocarcinoma (Cell Line: DU-145) [10]
Terameprocol + Methotrexate DCYKBBC Terameprocol Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Thioguanine + Methotrexate DCFSMN2 Thioguanine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [9]
Thioguanine + Methotrexate DC375FB Thioguanine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Thioguanine + Methotrexate DC0AP08 Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [9]
Thioguanine + Methotrexate DCYLDX2 Thioguanine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [9]
Thioguanine + Methotrexate DCK20TQ Thioguanine Clear cell renal cell carcinoma (Cell Line: 786-0) [9]
Thioguanine + Methotrexate DC0PWKS Thioguanine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [9]
Thioguanine + Methotrexate DC9FVJR Thioguanine Glioma (Cell Line: SF-268) [9]
Thioguanine + Methotrexate DCZV0O7 Thioguanine Papillary renal cell carcinoma (Cell Line: ACHN) [9]
Thioguanine + Methotrexate DC4RAO1 Thioguanine Renal cell carcinoma (Cell Line: SN12C) [9]
Thioguanine + Methotrexate DCZS4C9 Thioguanine Invasive ductal carcinoma (Cell Line: T-47D) [8]
Thioguanine + Methotrexate DCRZBJN Thioguanine Adenocarcinoma (Cell Line: DU-145) [10]
Thioguanine + Methotrexate DCPM9UD Thioguanine Amelanotic melanoma (Cell Line: M14) [10]
Thioguanine + Methotrexate DC0741Z Thioguanine Lung adenocarcinoma (Cell Line: MDA-MB-231) [10]
Tindamax + Methotrexate DCMJLCO Tindamax Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Topotecan + Methotrexate DCKYX82 Topotecan Lung adenocarcinoma (Cell Line: MDA-MB-231) [10]
Topotecan + Methotrexate DCC7GEC Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [10]
Topotecan + Methotrexate DCC8052 Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [10]
Triapine + Methotrexate DC99S4S Triapine Colon carcinoma (Cell Line: KM12) [8]
Trifluridine + Methotrexate DCR3KYR Trifluridine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [10]
Trihexyphenidyl + Methotrexate DCQ4WRT Trihexyphenidyl Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Triiodothyronine + Methotrexate DCN5JNX Triiodothyronine Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Trioxsalen + Methotrexate DC1602X Trioxsalen Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
Uracil mustard + Methotrexate DCHM14G Uracil mustard Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [9]
Uracil mustard + Methotrexate DCL7JUM Uracil mustard Clear cell renal cell carcinoma (Cell Line: 786-0) [9]
Uracil mustard + Methotrexate DCV8F0H Uracil mustard Glioma (Cell Line: SF-295) [9]
Uracil mustard + Methotrexate DC2CEIV Uracil mustard Plasma cell myeloma (Cell Line: RPMI-8226) [9]
Valrubicin + Methotrexate DCLAEIE Valrubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Valrubicin + Methotrexate DC0AXBY Valrubicin Astrocytoma (Cell Line: U251) [9]
Valrubicin + Methotrexate DCDEUSY Valrubicin Clear cell renal cell carcinoma (Cell Line: A498) [9]
Valrubicin + Methotrexate DC70L1L Valrubicin Invasive ductal carcinoma (Cell Line: T-47D) [8]
Valrubicin + Methotrexate DC46UX5 Valrubicin Adenocarcinoma (Cell Line: NCIH23) [10]
Valrubicin + Methotrexate DCY5MTH Valrubicin Adenocarcinoma (Cell Line: HCC-2998) [10]
Valrubicin + Methotrexate DCLFSO1 Valrubicin Large cell lung carcinoma (Cell Line: NCI-H460) [10]
Valrubicin + Methotrexate DCMOP29 Valrubicin Lung adenocarcinoma (Cell Line: MDA-MB-231) [10]
Valrubicin + Methotrexate DC7I1KT Valrubicin Melanoma (Cell Line: SK-MEL-2) [10]
Vandetanib + Methotrexate DCR9TFG Vandetanib Adenocarcinoma (Cell Line: SW-620) [10]
Vandetanib + Methotrexate DCNJQD9 Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-28) [10]
Vemurafenib + Methotrexate DC0ZUOC Vemurafenib Colon carcinoma (Cell Line: KM12) [8]
Vemurafenib + Methotrexate DC8B7IC Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [8]
Vemurafenib + Methotrexate DC3FRLD Vemurafenib Malignant melanoma (Cell Line: UACC62) [10]
Vinflunine + Methotrexate DCEMGRP Vinflunine Prostate carcinoma (Cell Line: PC-3) [10]
Vismodegib + Methotrexate DCO4QM3 Vismodegib Colon carcinoma (Cell Line: KM12) [8]
Vismodegib + Methotrexate DC97S3X Vismodegib Adenocarcinoma (Cell Line: HCC-2998) [10]
Vismodegib + Methotrexate DCP3FLI Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [10]
Vismodegib + Methotrexate DCM43QT Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [10]
Vismodegib + Methotrexate DCY0MD3 Vismodegib Malignant melanoma (Cell Line: UACC62) [10]
Zaleplon + Methotrexate DCG4R0Y Zaleplon Chronic myelogenous leukemia (Cell Line: KBM-7) [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 500 DrugCom(s)
84 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Baricitinib + Methotrexate DC23FEJ Baricitinib Arthritis, Rheumatoid [11]
Cyclophosphamide + Methotrexate DCRBM5R Cyclophosphamide Adult Acute Myeloid Leukemia in Remission [12]
Cyclophosphamide + Methotrexate DCB1Z2I Cyclophosphamide Mucopolysaccharidosis [13]
Cyclophosphamide + Methotrexate DCNF8YP Cyclophosphamide Breast Cancer [14]
Cyclophosphamide + Methotrexate DC3JOEX Cyclophosphamide Adult Acute Lymphoblastic Leukemia in Remission [15]
Cyclophosphamide + Methotrexate DCDS5IT Cyclophosphamide Breast Cancer Female [16]
Dexamethasone + Methotrexate DCW6FDO Dexamethasone B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 [17]
Methotrexate + Carboplatin DCSIJ0Q Carboplatin Osteosarcoma [18]
Methotrexate + Ondansetron DC0GFSX Ondansetron Juvenile Idiopathic Arthritis [19]
Methotrexate + Bortezomib DC0MTOY Bortezomib Graft Versus Host Disease [20]
Methotrexate + Methotrexate DC1N5HJ Methotrexate Recurrence (Disease Attribute) [21]
Methotrexate + Mycophenolate mofetil DC2P00C Mycophenolate mofetil Acute Leukemia [22]
Methotrexate + Sulfasalazine DCL7YBJ Sulfasalazine Chronic Nonbacterial Osteomyelitis [23]
Methotrexate + Azathioprine DCLPML3 Azathioprine Inflammatory Bowel Disease [24]
Methotrexate + Mercaptopurine DC0YH58 Mercaptopurine Recurrent Childhood Acute Lymphoblastic Leukemia [25]
Methotrexate + Prednisolone DC1Q8UQ Prednisolone Polymyositis [26]
Methotrexate + Asp-015K DC5F8IO Asp-015K Arthritis, Rheumatoid [27]
Methotrexate + Tofacitinib DC5IQZT Tofacitinib Rheumatoid Arthritis [28]
Methotrexate + Cytarabine DC69XSL Cytarabine Lymphoma [29]
Methotrexate + Vinblastine DCA6BWO Vinblastine Desmoid Tumor [30]
Methotrexate + Vinblastine DCBGXKZ Vinblastine Neurofibromatosis Type 1 [31]
Methotrexate + Tacrolimus DCBITQN Tacrolimus Leukemia, Myelocytic, Acute [32]
Methotrexate + Bexarotene DCERZFR Bexarotene Primary Cutaneous Anaplastic Large Cell Lymphoma [33]
Methotrexate + Leucovorin DCF4EMZ Leucovorin Brain Tumor [34]
Methotrexate + Thiotepa DCJWKYY Thiotepa Brain and Central Nervous System Tumors [35]
Methotrexate + Cyclosporin A DCK7VO5 Cyclosporin A Graft vs Host Disease [36]
Methotrexate + Prednisolone DCLRI0S Prednisolone Erythema Nodosum Leprosum [37]
Methotrexate + Tacrolimus DCMBK7X Tacrolimus Graft Versus Host Disease [20]
Methotrexate + Cyclosporin A DCNO2DZ Cyclosporin A Neoplasm Metastasis [38]
Methotrexate + Bucillamine DCS35QB Bucillamine Rheumatoid Arthritis [39]
Methotrexate + Imatinib DCZUUZW Imatinib Rheumatoid Arthritis [40]
Methotrexate + AC220 DC123FL AC220 Lymphoblastic Leukemia, Acute, Childhood [41]
Methotrexate + Loratadine DC832YA Loratadine Rheumatoid Arthritis [42]
Methotrexate + Fludarabine DCSJX87 Fludarabine Acute Myeloid Leukemia [43]
Methotrexate + Clofarabine DC26KNS Clofarabine Leukemia [44]
Methotrexate + Rifampicin DCEAFKR Rifampicin Drug Interaction [45]
Methotrexate + Bortezomib DCEQO1B Bortezomib Hematologic Malignancies [46]
Methotrexate + Thiotepa DCRVSCR Thiotepa Lymphoma [47]
Methotrexate + Febuxostat DC6MNXU Febuxostat Drug Interaction [45]
Methotrexate + Rifampicin DC6YRVT Rifampicin Drug Interaction [45]
Methotrexate + Isavuconazole DCBTZ9I Isavuconazole Pharmacokinetics of Isavuconazole [48]
Methotrexate + Leucovorin DCZI61X Leucovorin Rheumatoid Arthritis [49]
Pentostatin + Methotrexate DC67YIW Pentostatin Leukemia [50]
Cannabidiol + Methotrexate DCZAKYG Cannabidiol Graft vs Host Disease [51]
Cyclophosphamide + Methotrexate DCACZHQ Cyclophosphamide Adult Acute Myeloid Leukemia in Remission [52]
Cyclophosphamide + Methotrexate DCVLUL9 Cyclophosphamide Aplastic Anemia [53]
Dexamethasone + Methotrexate DCIWJEH Dexamethasone Acute Lymphoblastic Leukemia [54]
Dexamethasone + Methotrexate DCCALVA Dexamethasone Acute Lymphoblastic Leukemia [55]
Methotrexate + Procarbazine DC04JPN Procarbazine Chemotherapeutic Agent Toxicity [56]
Methotrexate + Treosulfan DC7ZS1W Treosulfan Accelerated Phase Chronic Myelogenous Leukemia [57]
Methotrexate + Cyclosporin A DCB7FI1 Cyclosporin A Accelerated Phase Chronic Myelogenous Leukemia [58]
Methotrexate + Fludarabine DCPTTD8 Fludarabine Accelerated Phase Chronic Myelogenous Leukemia [59]
Methotrexate + Mycophenolate mofetil DCX9VKT Mycophenolate mofetil Chronic Myeloproliferative Disorders [60]
Methotrexate + Maraviroc DCZMDCP Maraviroc Graft-versus-host Disease [61]
Methotrexate + Temozolomide DC31FMS Temozolomide Primary Central Nervous System Lymphoma [62]
Methotrexate + Atorvastatin DC838W5 Atorvastatin Acute Myelogenous Leukemia [63]
Methotrexate + Bortezomib DCJI1O7 Bortezomib Leukemia [64]
Methotrexate + Azathioprine DCL4PX4 Azathioprine Mucous Membrane Pemphigoid [65]
Methotrexate + Vorinostat DCMHPS9 Vorinostat Graft vs Host Disease [66]
Methotrexate + Maraviroc DCWL1XT Maraviroc Acute Leukemia [67]
Methotrexate + Thioguanine DCWQ945 Thioguanine Hodgkin's Disease [68]
Methotrexate + Colchicine DCG5MN4 Colchicine Coronary Artery Disease [69]
Methotrexate + Leucovorin DCKS8UJ Leucovorin Osteosarcoma [70]
Methotrexate + Mycophenolic acid DCNPZIX Mycophenolic acid Acute Myeloid Leukemia (AML) [71]
Methotrexate + Temozolomide DCO4NWS Temozolomide Primary CNS Lymphoma [72]
Methotrexate + Cytarabine DCW9ZZE Cytarabine Diffuse Large B Cell Lymphoma [73]
Cyclophosphamide + Methotrexate DC2HDW8 Cyclophosphamide B-cell Childhood Acute Lymphoblastic Leukemia [74]
Dexamethasone + Methotrexate DCEEIW2 Dexamethasone Leukemia [75]
Methotrexate + Atorvastatin DCA69PQ Atorvastatin Acute Myeloid Leukemia [76]
Methotrexate + Mycophenolate mofetil DCXC09Y Mycophenolate mofetil Chronic Myelogenous Leukemia [77]
Methotrexate + Paroxetine DCPUUM8 Paroxetine Rheumatoid Arthritis [78]
Methotrexate + Docetaxel DCQK0OU Docetaxel Head and Neck Squamous Cell Cancer [79]
Dexamethasone + Methotrexate DCM6UWN Dexamethasone Ph+ Acute Lymphoblastic Leukemia [80]
Methotrexate + Azathioprine DC08DRK Azathioprine Crohn's Disease [81]
Methotrexate + Mycophenolate mofetil DC3OAEB Mycophenolate mofetil Hematopoietic Stem Cell Transplantation [82]
Methotrexate + Sulfasalazine DC4YGOL Sulfasalazine Rheumatoid Arthritis [83]
Methotrexate + Sulfasalazine DC5KP7N Sulfasalazine Arthritis, Rheumatoid [84]
Methotrexate + Mycophenolate mofetil DC61B0K Mycophenolate mofetil Beta-Thalassemia Major [85]
Methotrexate + Sulfasalazine DC9EHO7 Sulfasalazine Psoriatic Arthritis [86]
Methotrexate + Acitretin DCJN91L Acitretin Plaque Psoriasis [87]
Methotrexate + Leflunomide DCAC3BT Leflunomide Rheumatoid Arthritis [88]
Methotrexate + Brilinta DCFZS7F Brilinta Rheumatoid Arthritis [89]
Methotrexate + Tofacitinib DCI20T9 Tofacitinib Rheumatoid Arthritis [90]
Simvastatin + Methotrexate DCYGZL1 Simvastatin Arthritis, Rheumatoid [91]
------------------------------------------------------------------------------------
⏷ Show the Full List of 84 DrugCom(s)

References

1 Methotrexate FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 040632.
3 Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for ... Trials. 2015 Mar 4;16:77.
4 ClinicalTrials.gov (NCT04136366) The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT04352465) Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients. U.S. National Institutes of Health.
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034238)
7 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
8 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
9 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
10 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
11 ClinicalTrials.gov (NCT01185353) A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy
12 ClinicalTrials.gov (NCT00445744) Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
13 ClinicalTrials.gov (NCT01238328) Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis
14 ClinicalTrials.gov (NCT00022516) Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer
15 ClinicalTrials.gov (NCT02122081) Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
16 ClinicalTrials.gov (NCT03518242) Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer
17 ClinicalTrials.gov (NCT01371630) Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
18 ClinicalTrials.gov (NCT00673179) Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy
19 ClinicalTrials.gov (NCT04169828) The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis
20 ClinicalTrials.gov (NCT01754389) Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
21 ClinicalTrials.gov (NCT02320630) Combination Therapy Prevents the Relapse of RA
22 ClinicalTrials.gov (NCT02487069) Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
23 ClinicalTrials.gov (NCT04725422) CHronic Nonbacterial Osteomyelitis International Registry (CHOIR)
24 ClinicalTrials.gov (NCT02413047) Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator
25 ClinicalTrials.gov (NCT00089349) Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
26 ClinicalTrials.gov (NCT00651040) Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM
27 ClinicalTrials.gov (NCT01554696) A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
28 ClinicalTrials.gov (NCT01745055) Co-Administration Of Methotrexate And CP-690,550
29 ClinicalTrials.gov (NCT00003311) Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
30 ClinicalTrials.gov (NCT00003019) Vinblastine and Methotrexate in Treating Children With Desmoid Tumors
31 ClinicalTrials.gov (NCT00030264) Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
32 ClinicalTrials.gov (NCT00406393) Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
33 ClinicalTrials.gov (NCT01578499) A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
34 ClinicalTrials.gov (NCT01737671) Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study
35 ClinicalTrials.gov (NCT00621036) Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
36 ClinicalTrials.gov (NCT01788501) Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease
37 ClinicalTrials.gov (NCT03775460) Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum
38 ClinicalTrials.gov (NCT00001880) Stem Cell Transplantation for Metastatic Solid Tumors
39 ClinicalTrials.gov (NCT00716248) Bucillamine Study of Holding Remission After Infliximab Dose-off
40 ClinicalTrials.gov (NCT00154336) A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.
41 ClinicalTrials.gov (NCT01411267) AC220 for Children With Relapsed/Refractory ALL or AML
42 ClinicalTrials.gov (NCT01390441) A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)
43 ClinicalTrials.gov (NCT02129582) Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
44 ClinicalTrials.gov (NCT00372619) Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
45 ClinicalTrials.gov (NCT05575297) A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin and Febuxostat on the Pharmacokinetics of Methotrexate in Healthy Subjects
46 ClinicalTrials.gov (NCT00369226) Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
47 ClinicalTrials.gov (NCT02724904) Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
48 ClinicalTrials.gov (NCT01884636) A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate
49 ClinicalTrials.gov (NCT03131973) Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin
50 ClinicalTrials.gov (NCT00506922) Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
51 ClinicalTrials.gov (NCT02478424) Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease
52 ClinicalTrials.gov (NCT00005940) Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission
53 ClinicalTrials.gov (NCT00343785) Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant
54 ClinicalTrials.gov (NCT03117751) Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
55 ClinicalTrials.gov (NCT04329325) Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
56 ClinicalTrials.gov (NCT01399372) Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
57 ClinicalTrials.gov (NCT00860574) Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
58 ClinicalTrials.gov (NCT01789255) Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
59 ClinicalTrials.gov (NCT01056614) Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
60 ClinicalTrials.gov (NCT00281879) Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
61 ClinicalTrials.gov (NCT02799888) Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation
62 ClinicalTrials.gov (NCT04514393) Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
63 ClinicalTrials.gov (NCT01491958) Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
64 ClinicalTrials.gov (NCT01323920) Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
65 ClinicalTrials.gov (NCT05263505) Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
66 ClinicalTrials.gov (NCT01790568) Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
67 ClinicalTrials.gov (NCT02208037) Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
68 ClinicalTrials.gov (NCT00587873) Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)
69 ClinicalTrials.gov (NCT02366091) Inflammation and Coronary Endothelial Function
70 ClinicalTrials.gov (NCT02022358) Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
71 ClinicalTrials.gov (NCT02416388) Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
72 ClinicalTrials.gov (NCT02934204) Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma
73 ClinicalTrials.gov (NCT03719560) Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma
74 ClinicalTrials.gov (NCT00382109) Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
75 ClinicalTrials.gov (NCT00707083) Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
76 ClinicalTrials.gov (NCT03066466) Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
77 ClinicalTrials.gov (NCT01951885) Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
78 ClinicalTrials.gov (NCT06231745) Paroxetine Safety and Efficacy in Rheumatoid Arthritis
79 ClinicalTrials.gov (NCT02252042) Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
80 ClinicalTrials.gov (NCT02690922) Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients
81 ClinicalTrials.gov (NCT02177071) A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
82 ClinicalTrials.gov (NCT04203108) ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
83 ClinicalTrials.gov (NCT03813771) Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-nave Early RA Patients Based on nave T-cell Stratification
84 ClinicalTrials.gov (NCT02374021) Treatments Against RA and Effect on FDG-PET/CT
85 ClinicalTrials.gov (NCT02342145) Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major
86 ClinicalTrials.gov (NCT03739853) Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
87 ClinicalTrials.gov (NCT04239859) Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis
88 ClinicalTrials.gov (NCT02275299) Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis
89 ClinicalTrials.gov (NCT02874092) Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis
90 ClinicalTrials.gov (NCT02831855) Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis
91 ClinicalTrials.gov (NCT04177173) Methotrexate and Statins With Methotrexate Alone in the Treatment of Rheumatoid Arthritis